Table 5.
Effect of antipsychotic treatment on gene expression pattern in peripheral blood of SCZ affected individuals.
| Gene name | Gene symbol | Pre treatment | Post treatment | Chromosomal location | ||
|---|---|---|---|---|---|---|
| Dopamine receptor D3 (Vogel et al., 2004) | DRD3 | ↓ | – | 3q13.31 | ||
| Very low density lipoprotein receptor (Suzuki et al., 2008) | VLDLR | ↓ | ↑ | 9p24.2 | ||
| LDL receptor related protein 8 (Suzuki et al., 2008) | LRP8 | – | ↓ | 1p32.3 | ||
| Neuregulin 1 (Zhang et al., 2008) | NRG1 | ↓ | ↑ | 8p12 | ||
| Transforming growth factor beta receptor 2 (Numata et al., 2008) | TGFBR2 | ↑ | ↓ | 3p24.1 | ||
| Neurolysin (Kuzman et al., 2009) | NLN | ↑ | ↓ | 5q12.3 | ||
| Disheveled associated activator of morphogenesis 2 (Kuzman et al., 2009) | DAAM2 | ↑ | – | 6p21.2 | ||
| Solute carrier family 2 member 3 (Kuzman et al., 2009) | SLC2A3 | ↑ | – | 12p13.31 | ||
| AKT serine/threonine kinase 1 (Kumarasinghe et al., 2013; Xu et al., 2016) | AKT1 | ↑↑ | – ↑ | 14q32.33 | ||
| Retinoid X receptor alpha (Kumarasinghe et al., 2013) | RXRA | ↑ | – | 9q34.2 | ||
| Matrix metallopeptidase 9 (Kumarasinghe et al., 2013) | MMP9 | ↑ | – | 20q13.12 | ||
| DISC1 scaffold protein (Kumarasinghe et al., 2013) | DISC1 | ↑ | ↑ | 1q42.2 | ||
| Ribosomal protein S25 (Kumarasinghe et al., 2013) | RPS25 | ↓ | – | 11q23.3 | ||
| DiGeorge syndrome critical region gene 6 (Kumarasinghe et al., 2013) | DGCR6 | ↓ | – | 22q11.21 | ||
| mal, T cell differentiation protein (Kumarasinghe et al., 2013) | MAL | ↓ | – | 2q11.1 | ||
| Myelin basic protein (Ota et al., 2015) | MBP | ↑ | – | 18q23 | ||
| nudE neurodevelopment protein 1 like 1 (Ota et al., 2015) | NDEL1 | ↑ | – | 17p13.1 | ||
| BRCA1 DNA repair associated (Xu et al., 2016) | BRCA1 | ↑ | – | 17q21.31 | ||
| Coiled-coil domain containing 134 (Xu et al., 2016) | CCDC134 | – | ↓ | 22q13.2 | ||
| Ubiquitin D (Xu et al., 2016) | UBD | – | ↓ | 6p22.1 | ||
| Zic family member 2 (Xu et al., 2016) | ZIC2 | – | ↓ | 13q32.3 | ||
| Cyclin dependent kinase 4 (Okazaki et al., 2016) | CDK4 | ↓ | ↑ | 12q14.1 | ||
| Minichromosome maintenance complex component 7 (Okazaki et al., 2016) | MCM7 | ↓ | – | 7q22.1 | ||
| DNA polymerase delta 4, accessory subunit (Okazaki et al., 2016) | POLD4 | ↓ | ↑ | 11q13.2 | ||
| Haptoglobin (Yee et al., 2017) | HP | ↑ | ↑ | 16q22.2 | ||
| Eukaryotic translation initiation factor 2D (Gilabert-Juan et al., 2019) | EIF2D | ↓ | ↓ | 1q32.1 | ||
| Signal transducer and activator of transcription 3 (Subbanna et al., 2020) | STAT3 | ↑ | ↓ | 17q21.2 | ||
The “↑” indicates up-regulation, “↓” indicates down-regulation and “–” indicates no change in the expression levels. The gene expression changes recorded in the post treatment column are with respect to the baseline expression levels and/or with respect to controls in the given study. The gene names and gene symbols mentioned in the table are HGNC approved.